<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744587</url>
  </required_header>
  <id_info>
    <org_study_id>T2312</org_study_id>
    <nct_id>NCT01744587</nct_id>
  </id_info>
  <brief_title>Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients</brief_title>
  <acronym>NPC</acronym>
  <official_title>Study of Epstein-Barr Virus Reactivation and the Effect of Dietary Supplement Epigallocatechin Gallate (EGCG) on Virus Reactivation in Remission Patients With Nasopharyngeal Carcinoma - A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the EBV reactivation rate in post-radiation and
      remission NPC patients, evaluate the safety and tolerance of EGCG and analyze the
      observational correlation between EBV reactivation and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pathologically proven NPC, stage II-IVB and finishing curative RT ≧70 Gy within
      6 months (± induction/concurrent/adjuvant chemotherapy) will be candidates for this study.
      Before entry, 8 CC venous blood will be obtained for EBV DNA and antibody screen tests after
      patient's consent. Those who have undetectable plasma EBV DNA (0 copy/ml) and fulfilled with
      all inclusion and exclusion criteria will be registered.

      Routine re-staging work-ups after RT should show no active lesion in nasopharynx, neck and
      distant organs. Re-staging survey should include nasopharyngoscope, pEBV DNA assay, CBC,
      platelet count, renal and liver function tests, CXR, abdominal sonography or CT scan, whole
      body bone scan, MRI or CT scan of the head and neck region.

      Within one week after finishing registration, EGCG or placebo should be started. A blood
      sample before taking EGCG/placebo will be collected for antibodies test and pEBV DNA assay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EBV reactivation rates between EGCG and placebo group</measure>
    <time_frame>every 3 months for the first 3 years and every 6 months thereafter for antibodies tests and pEBV DNA assay (total 5 years)</time_frame>
    <description>Reactivation of EBV is defined as
1.Antibody against EBV VCA: The IgA antibody titers will be detected by a commercial EBV VCA ELISA kit (RE 562 71, Immuno-Biological Laboratories, Germany) Patient's serum with anti-EBV VCA greater than 10U/ml will be considered as reactivation of EBV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between EBV reactivation and OS/RFS</measure>
    <time_frame>q 3 months for first 3 years and q 6 months for the</time_frame>
    <description>Observational analysis of the correlation between EBV reactivation and clinical outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>NPC</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo qd (2# bid) for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epigallocatechin Gallate (EGCG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGCG 600 mg qd (2# bid) for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epigallocatechin Gallate (EGCG)</intervention_name>
    <description>EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.</description>
    <arm_group_label>Epigallocatechin Gallate (EGCG)</arm_group_label>
    <other_name>EGCHAC-purified EGCG 90% capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo qd (2# bid) for 3 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven NPC.

          -  2010 AJCC stage II-IVB.

          -  Age ≧ 20 years old.

          -  Performance status of ECOG ≦ 2.

          -  Finished RT ≧66 Gy within 6 months (± induction/concurrent/adjuvant chemotherapy).

          -  Clinical complete remission by re-staging work-ups within 3 months before entry.

          -  Plasma EBV DNA = 0 copy/ml within 4 weeks before entry.

          -  Adequate liver, renal, and bone marrow function:Serum total bilirubin level ≦ 2.5
             mg/dl. Serum creatinine ≦ 1.6 mg/dl. WBC ≧ 3,000/ul. Platelet count ≧ 100,000/ul.

          -  No intake of EGCG or similar dietary supplements.

          -  Signed informed consent.

          -  No further anti-cancer treatment.

        Exclusion Criteria:

          -  Occurrence of locoregional recurrence or distant metastasis.

          -  Inadequate RT or finishing RT &gt; 6 months.

          -  Not complete remission by re-staging work-ups within 3 months before entry.

          -  Plasma EBV DNA &gt; 0 copy/ml within 4 weeks before entry.

          -  Intake of EGCG or similar dietary supplements during recent 3 months.

          -  Severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or
             peripheral vascular disease requiring hospitalization within the last 12 months;
             chronic obstructive pulmonary disease exacerbation other respiratory illness requiring
             hospitalization) or clinically significant psychiatric disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsang Wu Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Taiwan Cooperative Oncology Group, National Health Research Institutes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Ch Lin, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jen Ya Chen, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cancer Research, National Health Research Institutes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Ch Lin, MD PHD</last_name>
    <phone>+856-4-23592525</phone>
    <phone_ext>5613</phone_ext>
    <email>jclin@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yung Hs Chin, MSN</last_name>
    <phone>+886-37-246-166</phone>
    <phone_ext>35119</phone_ext>
    <email>yhchin@nhri.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taiwan Cooperative Oncology Group, National Health Research Institutes</name>
      <address>
        <city>Zhunan</city>
        <state>Miaoli</state>
        <zip>350</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Ch Lin, MD PHD</last_name>
      <phone>+8864-23592525</phone>
      <phone_ext>5613</phone_ext>
      <email>jclin@vghtc.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Tsang Wu Liu, MD</last_name>
      <phone>+886-37-246166</phone>
      <phone_ext>35120</phone_ext>
      <email>walter@nhri.org.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Jin Ch Lin, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Fa Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen Ch Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenn Re Hsiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EBV</keyword>
  <keyword>EGCG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

